心胸比率作为心力衰竭的预后标志物,具有保存的喷射分数
Masato Okada1, Koichi Inoue2, Toshinari Onishi3
1Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital, Osaka, Japan.
Journal of cardiology
|September 16, 2025
概括
胸部X射线上的心胸比率 (CTR) 表明心力衰竭与保存的喷射分数 (HFpEF) 严重程度. 增加的CTR (≥60%) 独立预测不良结果,有助于HFpEF患者的风险分层.
科学领域:
- 心脏病学 心脏病学
- 放射学 放射学是一门学科.
- 医疗成像医学成像
背景情况:
- 来自胸部X射线的心胸比率 (CTR) 是心脏大小的标准度量,在心脏病中具有预后影响.
- 它在心力衰竭中具有保存的喷射分数 (HFpEF) 的实用性,特别是关于心声回声学发现和临床结果的实用性,尚未得到充分证实.
研究的目的:
- 调查HFpEF患者中CTR和心声学参数之间的关联.
- 评估CTR在该人群中对不良临床结果的预后价值.
主要方法:
- 来自前性多中心PURSUIT-HFpEF注册表的数据分析.
- 包括1195名具有出院CTR数据的HFpEF患者,分为CTR<50%,50-59%和≥60%的类别.
- 评估CTR,心声回声指数和36个月临床结果 (死亡或HF再住院的综合结果) 之间的相关性.
主要成果:
- 较高的CTR与血液动力学受损和左心室和右侧腔室扩大相关,但与左心室体积无关.
- 死亡或HF再住院的事件率增加了较高的CTR类别 (44.2%对57.2%对65.2%).
- CTR ≥60%是不良结果的独立预测因子 (HR 1.47,95% CI 1.09-1.98).
结论:
- 在HFpEF中,高的CTR反映了血液动力学妥协和腔室扩大 (左心房,右侧),没有显著的LV腔扩张.
- 60%或更高的CTR是不良临床结果的独立预测指标.
- CTR是HFpEF患者风险分层的一个有价值的工具.
相关概念视频
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure IV: Classification and Diagnostic Evaluation
323
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
323
Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
500
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
500
Heart Failure I: Introduction
710
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
710
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480


